Testosterone

Generic Name: Testosterone

Brand Names: Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈O_₂

CAS Number: 58-22-0

Unique Ingredient Identifier: 3XMK78S47O

Background: Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication: Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer

Associated Therapies: -

Clinical Trials

ORAL T-6: Oral Androgens in Man-6

Phase 1

Completed

Conditions: Contraception
Hypogonadism

Interventions: Drug: Acyline
Drug: Testosterone
Drug: Finasteride

First Posted Date: 2008-04-22

Last Posted Date: 2011-01-24

Lead Sponsor: University of Washington

Target Recruit Count: 16

Registration Number: NCT00663793

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

Phase 1

Completed

Conditions: Hypogonadism

Interventions: Drug: testosterone

First Posted Date: 2008-04-01

Last Posted Date: 2018-03-30

Lead Sponsor: Acerus Pharmaceuticals Corporation

Target Recruit Count: 32

Registration Number: NCT00647868

Locations: 🇺🇸
Harbor - UCLA Medical Center, Torrance, California, United States

Testosterone in Castration-Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Testosterone

First Posted Date: 2007-12-20

Last Posted Date: 2013-04-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00577980

A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone

Phase 3

Completed

Conditions: Hypogonadism

Interventions: Drug: Testosterone

First Posted Date: 2007-08-29

Last Posted Date: 2017-10-05

Lead Sponsor: Endo Pharmaceuticals

Target Recruit Count: 149

Registration Number: NCT00522431

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: AndroGel
Drug: placebo

First Posted Date: 2007-08-13

Last Posted Date: 2014-06-11

Lead Sponsor: University of Chicago

Target Recruit Count: 6

Registration Number: NCT00515112

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 8 locations

Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure

Terminated

Conditions: Congestive Heart Failure

Interventions: Drug: testosterone

First Posted Date: 2007-08-07

Last Posted Date: 2008-10-17

Lead Sponsor: IRCCS San Raffaele

Registration Number: NCT00512408

Locations: 🇮🇹
IRCCS San Raffaele, Rome, Italy

Testosterone for Peripheral Vascular Disease

Phase 4

Completed

Conditions: Hypogonadism
Peripheral Vascular Disease
Type 2 Diabetes

Interventions: Drug: saline
Drug: Testosterone

First Posted Date: 2007-07-20

Last Posted Date: 2022-06-08

Lead Sponsor: Barnsley Hospital

Target Recruit Count: 24

Registration Number: NCT00504712

Locations: 🇬🇧
Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom

Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects

Phase 2

Conditions: Breast Cancer
Arthralgia
Osteoporosis

Interventions: Drug: Testosterone

First Posted Date: 2007-07-06

Last Posted Date: 2009-04-09

Lead Sponsor: Havah Therapeutics Pty Ltd

Target Recruit Count: 90

Registration Number: NCT00497458

Locations: 🇦🇺
Burnside Breast Centre, Adelaide, South Australia, Australia

TDSM- Testosterone Dose Response in Surgically Menopausal Women

Not Applicable

Completed

Conditions: Hysterectomy
Ovariectomy
Menopause
Testosterone Deficiency

Interventions: Drug: Testosterone

First Posted Date: 2007-06-29

Last Posted Date: 2013-05-01

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 270

Registration Number: NCT00494208

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

Not Applicable

Terminated

Conditions: Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism

Interventions: Drug: placebo
Drug: androgel

First Posted Date: 2007-05-01

Last Posted Date: 2024-02-06

Lead Sponsor: University at Buffalo

Target Recruit Count: 47

Registration Number: NCT00467987

Locations: 🇺🇸
Diabetes Endocrinology Research Center of WNY, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy